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Abstract
Objectives: Thrombus and secondary thrombosis plays a key role in stroke. Recent molecular imaging provides in vivo
imaging of activated factor XIII (FXIIIa), an important mediator of thrombosis or fibrinolytic resistance. The present study
was to investigate the fibrin deposition in a thromboembolic stroke mice model by FXIIIa–targeted near-infrared
fluorescence (NIRF) imaging.
Materials and Methods: The experimental protocol was approved by our institutional animal use committee. Seventy-six
C57B/6J mice were subjected to thromboembolic middle cerebral artery occlusion or sham operation. Mice were either
intravenously injected with the FXIIIa-targeted probe or control probe. In vivo and ex vivo NIRF imaging were performed
thereafter. Probe distribution was assessed with fluorescence microscopy by spectral imaging and quantification system. MR
scans were performed to measure lesion volumes in vivo, which were correlated with histology after animal euthanasia.
Results: In vivo significant higher fluorescence intensity over the ischemia-affected hemisphere, compared to the
contralateral side, was detected in mice that received FXIIIa-targeted probe, but not in the controlled mice. Significantly
NIRF signals showed time-dependent processes from 8 to 96 hours after injection of FXIIIa-targeted probes. Ex vivo NIRF
image showed an intense fluorescence within the ischemic territory only in mice injected with FXIIIa-targeted probe. The
fluorescence microscopy demonstrated distribution of FXIIIa-targeted probe in the ischemic region and nearby micro-
vessels, and FXIIIa-targeted probe signals showed good overlap with immune-fluorescent fibrin staining images. There was
a significant correlation between total targeted signal from in vivo or ex vivo NIRF images and lesion volume.
Conclusion: Non-invasive detection of fibrin deposition in ischemic mouse brain using NIRF imaging is feasible and this
technique may provide an in vivo experimental tool in studying the role of fibrin in stroke.
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Introduction
Stroke is the second leading cause of death worldwide and ranks
first for disablement.It isestimated that onesixth ofallhumanbeings
will suffer at least one stroke in their life time [1,2,3]. Thromboem-
bolic events are responsible for approximately 80% of human stroke
[4,5]. Dynamic imaging of thrombus and secondary thrombosis in
vivo can play a key role in understanding pathophysiology of stroke
after the occlusion of an intracranial artery and mechanism of
thrombolytic therapy.
With recent advances in near infrared (NIR)-activatable
fluorescent probe technology, near infrared fluorescence (NIRF)
imaging has been used in vivo to observe protease activity in a
murine stroke model [6,7]. NIRF imaging essentially depends on
the probes emitting in the NIR spectrum band width between
650–900 nm in which biological tissues display low absorption and
imaging shows high target-to-background ratios due to reduced
autofluorescence [8]. This technology offers several advantages
including high sensitivity and being radiation free, and it can be
performed with comparatively simple and inexpensive instrumen-
tation [7]. Although the major disavantage of weak penetration
with NIRF imaging hinders its clinical application currently, it is a
useful technique for investigating the pathological process of
diseases. Moreover, it may be potential clincial use by intraopera-
tion [9] or interventional procedures in the future.
Experimentally, activated factor XIII (FXIIIa), a thrombin
activated tetrameric transglutaminase, is an important mediator of
thrombosis or fibrinolytic resistance [10,11]. Recently, a near-
infrared fluorescent probe(A15) has been developed that is
recognized by FXIIIa [12]. It covalently binds to fibrin, providing
unique means to image the activity of the FXIIIa as well as to
visualize thrombus in vivo [11,13].
In this study, we investigated the potential use of the FXIIIa-
targeted probe for in vivo fibrin deposition in ischemic brain tissue
in a mouse thromboembolic stroke model. This study aims to
answer specifically: (a) whether the fluorescent probe targeting
fibrin could be used to identify and quantify fibrin deposition in
regions of cerebral ischemia in vivo and ex vivo, (b) whether the
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this fluorescent probe, (c) whether NIRF signal intensity for fibrin
deposition in regions of cerebral ischemia using this fluorescent
probe correlates with ischemic lesion volume.
Results
In vivo and ex vivo NIRF imaging
In vivo NIRF imaging (Figure 1A, Left) or ex vivo NIRF imaging
of the mouse brains removed from the skull (Figure 1A, Right)
showed no difference between right and left hemispheres in sham-
operated mice injected with the FXIIIa-targeted NIRF imaging
probe (A15). The rectangular regions give an example of the
Regionsofinterest(ROIs)placedover theright and left hemisphere.
Slightly higher fluorescence intensities over the injected hemisphere
compared with the contralateral side were detected in thrombo-
embolic middle cerebral artery occlusion (MCAO) mice injected
with the control C15 probe (only different than A15 at position 14
amino-acid residue) by both the in vivo NIRF image (Figure 1B,
Left) and the ex vivo NIRF image (Figure 1B, Right). Strong
fluorescence was seen over the ipsilateral side of MCAO mice
injected with the A15 probe on the in vivo NIRF image (Figure 1C,
Left) and the ex vivo NIRF image (Figure 1C, Right). The
corresponding ex vivo NIRF images showed equally low fluores-
cence intensities over both hemispheres in brains of sham-operated
mice that were injected with A15.
Sham-operated mice that received A15 and MCAO mice that
received C15 both showed statistically significant lower Target-to-
background ratios (TBRs) compared to MCAO mice that received
A15 (0.9560.06 and 1.1060.07 versus 1.6860.25, respectively;
P,0.05) (Figure 1 D).
Time courses of in vivo NIRF imaging of MCAO mice after
injection of A15
The results from noninvasive NIRF images obtained at different
time points after injection of A15 are shown in Figure 2. In mice
imaged with NIRF at 1 hour, 4 hours and 6 hours after injection of
A15, there was no significant difference observed between the
fluorescence intensities measured over the ipsilateral, ischemic
hemisphere compared with the contralateral side (TBRs:
0.9460.09, 1.0260.10 and 1.0260.09, respectively). In contrast,
significantly higher fluorescence signals were detected over the
ipsilateral hemisphere compared with the contralateral side in mice
imaged with NIRF at 8 hours, 16 hours, 20 hours, 24 hours,
48 hours, 72 hours and 96 hours (Figure 2A) after injection of A15
(TBRs: 1.1160.09, 1.3760.12, 1.4460.22, 1.6860.25, 1.6260.11,
1.4060.11 and 1.2160.12, respectively; n=6, P,0.05). Signifi-
cantly TBRs changes were clearly detected initially at 8 hours after
injection of A15, and it showed time-dependent increase until at
24 hours after injection. TBRs values also decrease gradually at 48,
72 and 96 hours (Figure 2B).
Figure 1. Representative NIRF imaging of different groups 24 h after infusion of the fluorescent probe. In vivo NIRF imaging (A, Left) or
ex vivo NIRF imaging of the mouse brains removed from the skull (A, Right) showed no difference between the hemispheres in sham-operated mice
injected with the A15 probe. The rectangular boxes represented the ROIs placed over the right and left hemisphere. There was only slight increase of
fluorescence intensities in the injected hemisphere compared with the contralateral side in MCAO mice injected with the C15 control probe (in vivo
NIRF imaging, B, Left; and ex vivo NIRF imaging, B, Right). Strong fluorescence was seen over the ipsilateral side of MCAO mice injected with the A15
probe shown by in vivo NIRF imaging (C, Left) or ex vivo NIRF imaging (C, Right). The images were normalized on the color scaling bar. Target-to-
background ratios (TBRs) were calculated from ROI analyses of noninvasive NIRF images in different groups as shown in Fig D. Only the MCAO mice
receiving the A15 probe showed significantly higher TBRs (*P,0.05 versus SHAM). Bar in (A–C)=5 mm.
doi:10.1371/journal.pone.0030262.g001
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A lesion was delineated by triphenyltetrazolium chloride (TTC)
staining at 24 hours after injection of clots in MCAO mice
injection of NIRF probes (Figure 3). In sham-operated mice
receiving A15, weak fluorescence was evenly distributed over the
brain slice. Areas of low fluorescence signals, corresponding to the
pallor in TTC staining, were seen in MCAO mice injected with
C15. Areas with high fluorescence signals were observed over the
ischemic region in MCAO mice that received A15. Ex vivo NIRF
imaging of brain slices, bilateral hemispheres showed differential
fluorescence intensities in the brains of MCAO mice 24 h after
injection of the A15 probe. Higher fluorescence signals were
observed in the ischemic lesion, corresponding to the pallor in
TTC staining, compared to areas surrounding the lesion (Figure 3
A, B). The highest fluorescence signals were detected in the cortex
of the ischemic hemisphere mainly (Figure 3A). The volumes were
calculated from A15 signal larger than from TTC ischemia lesion
(A15: 76.4867.14% and TTC: 64.76610.75%). Fluorescence
microscopy was used to assess the distribution of the A15 probe
with higher magnification. Intense, diffuse Cy5.5 fluorescence
from A15 was observed in the ischemic area of the cortex and
nearby micro-vessels (Figure 3C), whereas fluorescence is scarcely
visible in the non-ischemic area. The lesion border is delineated
after hematoxylin and eosin staining (Figure 3D).
Fluorescence Microscopy and Immunohistochemistry
In MCAO mice injected with A15 probe at 1, 8, 24 and
96 hours, Cy5.5 fluorescence was detected in the ischemic core.
The fluorescence from injected probes at different time points
(Figure 4B) revealed a similar pattern (Figure 4C) to the antibody
staining against the fibrin (Figure 4A). The embedded scatter gram
in the upper left corner of each image showed good overlap of
colocalization analysis (Figure 4C).
Relationship between targeted signals from NIRF
imaging and ischemic lesion volume
The targeted signals were separated and calculated by
multispectral imaging technology from MCAO mice that received
A15 (n=10) (Figure 5 A, B). Linear regression analysis showed a
significant correlation (R
2=0.526, P,0.05) between the total
targeted signal values of non-invasive NIRF images and the total
Figure 2. Time courses of in vivo NIRF imaging of MCAO mice injected with A15 at 6 h, 8 h, 20 h and 96 h (A). Quantification of target-
to-background ratios (TBRs) at different time points (From 0–96 h post injection of A15) was shown in B. The group that were significantly different
were compared with 0 h (TBRs=1). (*P,0.05 versus time 0).
doi:10.1371/journal.pone.0030262.g002
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observed over the ischemic region in MCAO mice that received A15 (A), corresponding to the pallor in TTC staining (B). High magnification of the
boxed region in A was shown in C (C, 406). Intense and diffuse Cy5.5 fluorescence from A15 was observed in the ischemic area of the cortex and
nearby micro-vessels (q), whereas fluorescence was scarcely visible in the nonischemic areas. The border between the ischemic and nonischemic
area was clearly delineated after TTC (B) and hematoxylin and eosin staining (D).
doi:10.1371/journal.pone.0030262.g003
Figure 4. Fluorescence images of brain sections showed the ipsilateral cortex of MCAO mice at 1, 8, 24 and 96 hours after
intravenous injection of A15. The green signals showed the staining with FITC-labeled antibodies against fibrin (A), and the red signals (NIRF
channel) displayed the distribution of the injected Cy5.5-labeled probes (B). The embedded scatter gram in the upper left corner of each image (C)
showed good overlap of colocalization analysis (C). (406, Bar=50 mm).
doi:10.1371/journal.pone.0030262.g004
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injected with the A15 probe (Figure 5D, Left).
No abnormal signal was seen in T2-weighted image (T2WI) of
sham-operated mice. At 24 h post injection of thrombus, hyper
intensity was detected in ipsilateral hemisphere of MCAO mice
(Figure 5C). In MCAO mice injected with the A15 probe (n=10),
linear regression analysis demonstrated a significant correlation
(R
2=0.483, P,0.05) between the value of total targeted signal of
in vivo NIRF imaging and percent of edema–corrected lesion
volume (%HLV
e) (Figure 5D, Middle). The values of total targeted
signal of ex vivo NIRF imaging against %HLV
e also showed a
linear correlation (R
2=0.843, P,0.05) (Figure 5D, Right).
Discussion
For the first time, our study demonstrated that a factor involved
in secondary fibrin deposition in cerebral ischemia could be
specifically and non-invasively revealed using an infrared probe
A15, and in vivo NIRF imaging in an animal model.
Microvascular fibrin deposition has been shown to accumulate
during early focal cerebral ischemia and reperfusion in the
nonhuman primate [14,15]; and fibrin-containing microthrom-
boemboli were found in acute human ischemic brain [16].
Previous studies have established a link between ischemic brain
injuries and reduced antithrombotic mechanism in brain micro-
circulation in the presence of major stroke risk factors [17,18].
Thrombosis starts with the activation of thrombin, which converts
soluble fibrinogen to fibrin [19].Visualization of fibrin distribution
in vivo without sacrificing the experimental animal is highly
desirable to study the pathophysiology and treatment of acute
stroke. Just like human ischemic stroke. The major advantage of
thromboembolic MCAO model used in this experiment is that it is
more similar to pathophysiology of ischemic stroke in humans.
NIRF imaging using fluorescent probes is a promising technology
for visualizing biological events noninvasively in small animals and
potentially in clinical settings [20]. An optical probe (A15), which
is based on the aminoterminus of alpha-2 antiplasmin and
covalently integrated into thrombi by means of the transglutamase
activity of FXIIIa, has been specifically developed for NIRF
imaging in vivo [10,11,13].
Time sequences were distinctively crucial in experimental
research of thrombolytic therapy in acute stroke models. Our
results confirmed that fibrin deposition after cerebral ischemia was
time-dependent, being most prominent at 24 hours [21]. Early
fibrin depositions in microvessels at 1 hour (1 h) after cerebral
ischemia have, however, been reported [16] and been observed in
this study. The A15 probe was tested within these time frames in
MCAO mice. At 1 h, 4 h, and 6 h there is no detectable
Figure 5. Quantitative analysis of targeted signals from in vivo and ex vivo NIRF imaging of the mouse brains removed from the
skull and lesion volume of T2WI (%HLV
e). The targeted signals of in vivo and ex vivo NIRF images are separated from background signals by
multispectral imaging technology (A). ROI was selected by threshold segmentation (B). Fig. 5C shows T2WI of MCAO mice 24 h after injection of A15,
and area of hyperintensity delineates ischemia lesion. A significant correlation is observed between the total targeted signal values of in vivo NIRF
images (R
2=0.526, P,0.05) and the total targeted signal values of ex vivo NIRF images of MCAO mice injected with the A15 probe (D, Left). A
significant correlation is observed between the value of total targeted signal from in vivo NIRF imaging (R
2=0.483, P,0.05) or from ex vivo NIRF
imaging (R
2=0.843, P,0.05) and lesion volume of T2WI (%HLV
e) (D, Middle, Right). Bar in (A–D)=5 mm.
doi:10.1371/journal.pone.0030262.g005
Fibrin-Targeted Imaging in Stroke
PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30262fluorescent activity in affected hemisphere using A15 probe.
Strong fluorescence intensities, on the other hand, were clearly
observed over the ischemic hemispheres compared with the non-
ischemic hemispheres on noninvasive and ex vivo NIRF images at
8 h after injection of A15, and strongest fluorescence intensities
were observed at 24 h after injection of A15. The fibrin
depositions in microvessels were time-dependent, and it decreased
gradually beyond 24 h after injection of A15. Noninvasive NIRF
imaging using A15 probe was able to reveal this course in vivo.
The A15 probe was injected in sham-operated mice as controls
for activation of the probe unrelated to cerebral ischemia. Low
fluorescence intensities were found equally distributed over both
ipsilateral and contralateral hemispheres on in vivo NIRF images.
To test the specificity of A15, a non-binding of control C15 probe
was also injected to MCAO mice. In those mice, there was no
difference between hemispheres seen based on in vivo NIRF
images using the control C15 probe. When the brains were
removed from the skull and imaged with NIRF ex vivo,
fluorescence intensities in the affected ispilateral brain tissue were
slightly higher than the contralateral brain tissue using the control
C15 probe. With C15, the amounts of fluorescent probes in the
ischemic tissue were clearly below the in vivo detection limit and
were nondetectable with noninvasive NIRF. In the MCAO mice
that received the A15 probe, focal high fluorescence was detected
in the ischemic region and nearby micro-vessels. In contrast, the
signal was rather diffuse and scarcely visible in MCAO mice that
received C15. The results suggest the binding of A15 probe is
largely attributable to specific affinity of the probe to fibrins in the
damaged tissue rather than to damaged tissue with impaired
blood– brain barrier. Ex vivo NIRF imaging of brain slices from
MCAO mice 24 h after injection of the A15 probe showed that
the highest fluorescence signal is concentrated mainly in the cortex
of the ischemic hemisphere. Fibrin deposition in the cortex is later
than in other regions of ischemic hemisphere. These results
support the hypothesis that fibrin deposition in the cortex is later
than other places such as the striatum of ischemic hemisphere,
because of existence of collateral blood vessels and the penumbra.
Edema-corrected LV calculation on MRI indicated lesion
accurately [22]. The values of total targeted signal from in vivo
or ex vivo NIRF images and the lesion size calculated using
%HLV
e of T2WI on MRI showed significant correlations. One
potential explanation is that micro-vessel obstructions by fibrin
deposition in the ischemic region have a close relationship with the
irreversibility of the damage from ischemic insults. This is
supported by the fact that anticoagulant therapy can diminish
lesion volumes of cerebral ischemia [23]. FXIII catalyzes
intermolecular cross-linking reactions between fibrin monomers,
2-plasmin inhibitor, and fibronectin. These reactions increase the
mechanical strength of the fibrin clot and its resistance to
proteolytic degradation, and enhance the assembly of the
extracellular matrix [10,24,25]. Noncontrolled cross-linking by
FXIIIa results in overcross- linked fibrin, and extensive cross-
linking of other plasma proteins to fibrin, that could lead to
undesired prolonged persistence of thrombi [26]. The stability of
fibrin was disclosed indirectly owing to activity of FXIII. The
linear correlation between the values of targeted signal in vivo or
ex vivo NIRF images and lesion volumes in T2WI supports the
hypothesis that fibrin depositions in the region of cerebral ischemia
play a key role in neuronal damage leading to cerebral infarction.
MRI has played a pivotal role in noninvasive acute stroke
research. MRI, however, has difficulty in demonstrating secondary
thrombosis in microcirculations directly. More recently, fibrin-
specific MR contrast agents have been reported to show coronary
and pulmonary clots, as well as cerebral venous sinus thrombosis,
and may have the ability to differentiate between the early phases
of thrombus formation and organized thrombi in carotid artery.
However, the sensitivity using the agent to demonstrate thrombi in
microvessels is poor [27,28]. On the other hand, NIRF imaging
has shown excellent sensitivity and specificity. The disadvantage of
NIRF imaging technique, on the other hand, is its lack of spatial
resolution. In the present study, combining MRI with NIRF
imaging allows for localization of biological signal to subtle
anatomical structures.
Although fibrinolytic therapies have been used extensively in the
treatment of strokes, the role of extravasated fibrin in the
rehabilitation of the CNS after the primary neuronal damage
caused by cerebral ischemia remains to be elucidated. Fibrin and
FXIIIa may regulate cell survival and apoptosis, modulate
migration, proliferation and cytokine secretion that play a pivotal
role in the orchestration of the immune response [26,29]. These
properties make fibrin a mediator of pathogenic effects that extend
beyond blood coagulation. The nervous tissue provides the
necessary receptors and intracellular signaling pathways to
mediate fibrin-induced cellular responses [30].The activation of
an enzyme such as FXIIIa and the deposition of fibrin would be
expected to serve as early predictors for the success or failure of a
therapeutic regimen in treatment of ischemic injuries to the brain.
We have shown that A15 may be used as a non-invasive probe to
study fibrin and cellular FXIII function in ischemic stroke. The
A15 agent could be expected to have utility in molecular imaging
to guide therapy with fibrinolytic or anti-FXIIIa agents, direct or
indirect thrombin inhibitors, or other drugs in the molecular
passways.
In conclusion, in vivo visualization and quantification of fibrin
deposition after cerebral ischemia using NIRF imaging is feasible
in the mouse model and may provide an experimental tool in
studying the role of fibrin in the pathophysiology of ischemic
stroke.
Materials and Methods
The synthesis of the FXIIIa-targeted NIRF imaging probe
The chemical synthesis of the FXIIIa-targeted NIRF imaging
probe was modified from the previous reference [12]. Briefly, the
FXIIIa affinity peptide, Ac-GN13QEQVSPLTLLK24WC, based
on the N-terminus of alpha-2-antiplasmin (a2-AP) was synthesized
by solid-phase peptide synthesis and then labeled with Cy 5.5
(Molecular Probes, Eugene, OR, USA) via its cysteine side chain.
The compound was purified using high-performance liquid
chromatography, resulting in the final FXIIIa-targeted NIRF
imaging agent (A15). The excitation and emission wavelengths of
A15 were 673 and 692 nm, respectively. A control probe modified
by replacing glutamine residue at position 14 with an alanine
residue to prevent binding to fibrin was also synthesized (C15).
Animals
This study was approved by Institutional Animal Care and Use
Committee (IACUC) of the Medical School of Southeast
University (approval ID: SYXK-2010.4987). A total of 76 male
C57BL/6J mice (28.5–32 g, Shanghai Laboratory Animal Center,
Chinese Academy of Science, China) were used in this study.
Animals were housed under standard conditions.
Animal model
Thromboembolic stroke mouse models were prepared as
described previously, with some modifications [23,31]. Briefly,
eight fibrin-rich 48-hr-old homologous cylindrical thrombus of
1.5 mm in length were injected from external carotid artery (ECA)
Fibrin-Targeted Imaging in Stroke
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OD=0.38 mm, Anilab, Ningbo, Zhejiang, China) catheter. Sham
operation was performed with the same surgical procedures but
without injection of the thrombus.
Experimental design
The experimental mice were divided into two groups randomly
(MCAO group, n=72 and sham group, n=4). NIRF imaging was
either performed at 1, 4, 6, 8, 16, 20, 24, 48, 72 and 96 h (MCAO,
n=6, 6, 6, 6, 6, 6, 10, 6, 6 and 5, respectively) with mice after the
injection of A15 probes or after the injection of (A15, sham, n=4
or C15, MCAO, n=6) probes at 24 h. The fluorescent
compounds were diluted in PBS (5 nmol/100 mL, per mouse)
and injected into the tail vein or femoral vein as a bolus
immediately after the injection of thrombus. T2-weighted MRI
images (T2WI) were obtained after NIRF imaging at 24 h post
thrombus injection. The MCAO mice without ischemic lesion in
T2WI (n=1, MCAO 24 h group) or dead mice (n=2, MCAO
24 h group and 96 h group) were excluded from further analysis.
For ex vivo NIRF imaging, the brains were removed under deep
anesthesia after MRI, and coronal brain slices of 1-mm thickness
were cut in a mice brain matrix using a razor blade.
In vivo NIRF imaging
Mice were fixed in an examining unit, and the skull exposed by
a longitudinal skin incision (about 2 cm) in all of the mice.
Fluorescent images were obtained with the Maestro in vivo
imaging system (CRi, Woburn, MA, USA) at predetermined time
points. Two filter sets (Red: excitation, 616–661 nm; Red:
emission: 675 nm Long pass; liquid crystal tunable filter (LCTF):
670 nm to 900 nm in 10 nm steps) were used to detect probe-
specific fluorescence (from PPCD conjugates) and auto-fluores-
cence (primarily from the skins and blood vessels). The fluorescent
images were then analysed based on their spectral patterns using
Maestro 2.10.0 Software (CRi, Woburn, MA, USA).
The fluorescence signals were separated by multispectral
imaging technology. The measurement was carried out in grey
level integration. ROIs analysis was performed by a person who
was blinded to the experimental groups. ROIs were selected by
threshold segmentation or manually drawn regions using the same
standard. For analysis of time points and group signal changes,
ROIs were selected manually by drawing regions on the in vivo
NIRF images. Rectangular ROIs were selected over the right and
left hemisphere using normalized NIRF in vivo images (Figure 1A,
Left). TBRs were defined as: (ROI values from the right
hemisphere)/(ROI values from the left hemisphere) [6,20].
Threshold segmentation of ROI selection for lesion quantification
was used for correlative analysis. The total signal (scaled-counts/s)
within the ROI was calculated.
Magnetic Resonance Imaging
Magnetic resonance imaging was performed on a high magnetic
field micro-MR research scanner (7.0T Bruker PharmaScans,
Bruker Biospin, Ettlingen, Germany). Data acquisition and image
processing were performed using a Paravision 5.0 software platform
(Bruker Biospin, Ettlingen, Germany). Mice were subjected to
isoflurane anesthesia. Respiratory rate and body temperature were
monitored using a physiology monitoring unit (Model 1025, SA
Instruments Inc, Stony Brook, NY, US), and temperature was
maintained within physiologic limits using an animal warming
system(MT1025,BrukerBiospin,Ettlingen,Germany).T2-weighted
images were generated using a two-dimensional turbo spin-echo
sequence (TR/TE=2,862/20 msecs, RARE factor 8, 4 averages).
Ten axial slices with a slice thickness of 1 mm, a field of view of
2.062.0 cmandamatrixof2566256werepositionedoverthebrain
excluding the olfactory bulb. Six coronal slices were positioned for
matching with NIRF images.
Computer-aided planimetric assessment of the lesion and
hemispheric volumes were performed using image analysis
software ImageJ (NIH, Bethesda, MD, USA). After adjustment
of contrast, the contours of the hemispheres were traced manually
on each slice. The position of the midline was determined using
neuroanatomic landmarks as described previously [22]. Lesion
volumes were determined by computer-aided manual tracing of
the hyper-intense lesions and corrected for the space-occupying
effect of brain edema as described previously using the following
equation [22].
%HLV
e=(HVc2HVi+LV)/HVc*100; Where %HLV
e indi-
cates edema–corrected lesion volume (in percent of the hemispheric
volume); HVc and HVi indicate contralateral and ipsilateral
hemispheric volume; and LV indicates uncorrected lesion volume.
Histological Examination
After ex vivo NIRF imaging, brain slices were incubated in a
2% TTC solution (Sigma Aldrich) at 37uC for 30 minutes.
Hematoxylin and eosin staining using 6 mm thickness brain
sections was performed to distinguish lesion border. The area of
infarction was assessed by drawing an outline of the area of TTC
pallor on scanned images of sections by an assessor blinded, and
the volume of infarction was calculated without edema correction,
to enable comparison with the ex vivo NIRF volumes.
Immunohistochemistry
At each time point after injection of A15 probe, animals were
anesthetized and transcardially perfused with heparinized saline
followed by 4% of paraformaldehyde. After postfixation and
dehydration, coronal sections (20 mm) of mouse brains were cut
on a freezing microtome. A rabbit polyclonal antibody against
fibrinogen/fibrin was used to detect the deposition of fibrin in brain
(at dilution of 1:500, Abcam, ab34629, Hong Kong). Sections were
incubated with the primary antibody against fibrinogen/fibrin for
1 d at 4uC, followed by incubation with the secondary antibody
(KPL, Kirkegaard & Perry Laboratories, Inc., NO. 02-15-06, MD,
US) conjugated to FITC.
Fluorescence Microscopy
A BX51 microscope with blue and red excitation filter units
(Olympus, Japan) and CRi Nuance spectral imaging and quanti-
fying system (Cambridge Research and Instrumentation Inc.,
Woburn, MA, USA) were used to examine the fluorescence signals
in sections. Allcubed image files were collected from the tissue slides
at 10 nm wavelength intervals from 420 nm to 720 nm or from
670 nm to 720 nm with auto exposure times at 4006magnifica-
tions. Both mixed and separated FITC and Cy5.5 images were
established after determining the FITC and Cy5.5 spectral library
and unmixing the cubes. Quantitative colocalization analysis was
performed using Image J (NIH, Bethesda, MD, USA).
Statistical Analysis
Data are presented as mean 6 SD. Comparisons were made
using analysis of variance on ranks followed by 1-way ANOVA
test, followed by Bonferroni post-test. Targeted signal values of in
vivo NIRF images were plotted against ex vivo NIRF images or
%HLV
e, followed by a linear regression analysis to calculate R
2
and to determine the regression equation. A value of P,0.05 was
considered statistically significant.
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